Latest News & Features
Big Pharma
Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030. 21 March 2023
Biotechnology
New R&D tax incentive announced for SMEs in UK Budget | Funding for medicines regulator aims to open up drug approvals | ‘Hidden benefits’ in Budget for industry | Reaction from Bioindustry Association, Potter Clarkson, Mischon de Reya, Marks & Clerk, Taylor Wessing. 16 March 2023
Medtech
Dispute relates to AstraZeneca ‘Breztri’ brand | Court says no likelihood of confusion with earlier marks | Full details of reasoning. 16 March 2023
Americas
Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning. 14 March 2023
Biotechnology
“Customer suit exception” is rejected by district judge | Suit between Chr. Hansen and Glycosyn is ongoing. 14 March 2023
Big Pharma
Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand. 9 March 2023
Big Pharma
The University of Minnesota had raised three key issues on appeal | Sovereign immunity was at the heart of the years-long dispute. 7 March 2023
Big Pharma
The Roche subsidiary says the licensee owes payments on “stockpile” of MS drug Tysabri. 7 March 2023
Big Pharma
Health-related patents fell during 2022 against a backdrop of record global patents filed | Biotechnology was fastest growing field among Patent Cooperation Treaty applications | COVID-19 pandemic caused large falls in goods classes such as pharmaceuticals. 2 March 2023
Biotechnology
Boehringer Ingelheim challenged university patent | Board must provide more details on ruling. 2 March 2023